Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Core Insights - Propanc Biopharma, Inc. is advancing its lead candidate PRP towards a Phase 1b clinical trial for advanced solid tumors, with significant progress in GMP manufacturing and patent drafting [2][3][4] - The company has successfully raised $4 million through a public offering and entered a private placement agreement for up to $100 million to accelerate clinical development [5][6] - Financial results for Q1 show a net loss of $4.84 million, with total current assets at $17 million and a reduction in total current liabilities by $2 million [9][15] Corporate and R&D Highlights - PRP is set to enter a Phase 1b clinical study involving 30-40 patients at the Peter Mac Cancer Center, with purification processes achieving over 95% purity [2] - Rec-PRP, a synthetic version of PRP, is undergoing biological validation and will enter preclinical development after potency evaluation [3] - The POP1 research program is being extended to further investigate PRP's effects on Gemcitabine-resistant pancreatic cancer [4] Financial Updates - The company completed a public offering of 1,000,000 shares at $4.00 per share, raising gross proceeds of $4 million [5] - A private placement facility of up to $100 million has been established, with an initial investment of $1 million received [6] - As of September 30, 2025, total current assets were reported at $17 million, with a quarter-end cash balance of $600,000 [9][15] Management Commentary - The CEO highlighted meaningful progress in clinical, financial, and strategic initiatives, emphasizing the focus on initiating the Phase 1b trial and expanding the intellectual property portfolio [8]